Leerink Partnrs Expects Reduced Earnings for REGENXBIO

Key Points

• Leerink Partners has revised its FY2025 earnings per share estimate for REGENXBIO to a loss of ($2.32), significantly lower than the previous estimate of ($1.64).
• The consensus estimate for REGENXBIO's full-year earnings currently stands at a loss of ($4.84) per share, reflecting broader challenges within the company.
• Multiple analysts have provided mixed ratings on REGENXBIO, with a "buy" rating from Chardan Capital and a downgrade to "strong sell" from Wall Street Zen.

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Research analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of REGENXBIO in a note issued to investors on Monday, August 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($2.32) for the year, down from their prior estimate of ($1.64). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's Q4 2025 earnings at $0.23 EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($2.98) EPS and FY2029 earnings at ($2.03) EPS.

A number of other analysts also recently weighed in on RGNX. Chardan Capital restated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Friday, August 8th. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Barclays dropped their target price on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. HC Wainwright restated a "buy" rating and issued a $34.00 target price on shares of REGENXBIO in a research report on Tuesday. Finally, Royal Bank Of Canada lowered their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $28.38.

REGENXBIO Price Performance

NASDAQ:RGNX opened at $8.07 on Thursday. The business has a 50 day moving average of $8.57 and a 200 day moving average of $8.06. The company has a market capitalization of $407.62 million, a price-to-earnings ratio of -2.35 and a beta of 1.11. REGENXBIO has a 1-year low of $5.03 and a 1-year high of $13.48.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). The business had revenue of $21.36 million for the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%.

Institutional Trading of REGENXBIO

Several hedge funds and other institutional investors have recently bought and sold shares of RGNX. Geode Capital Management LLC lifted its position in REGENXBIO by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock valued at $8,460,000 after purchasing an additional 5,574 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of REGENXBIO by 34.0% during the fourth quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock valued at $374,000 after buying an additional 12,285 shares during the period. Renaissance Technologies LLC purchased a new position in shares of REGENXBIO during the fourth quarter valued at approximately $2,097,000. Raymond James Financial Inc. purchased a new position in shares of REGENXBIO during the fourth quarter valued at approximately $568,000. Finally, Barclays PLC increased its stake in shares of REGENXBIO by 9.5% during the fourth quarter. Barclays PLC now owns 127,065 shares of the biotechnology company's stock valued at $982,000 after buying an additional 11,041 shares during the period. Institutional investors own 88.08% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.